FLEMINGTON, N.J.--(BUSINESS WIRE)--NovaDel Pharma Inc. (AMEX: NVD), a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed treatments, today announced data from its Pilot Efficacy Study of its Oral Spray formulation of sumatriptan (Sumatriptan OS) compared to sumatriptan tablets, marketed as Imitrex®/Imigran®, the leading triptan indicated for the treatment of migraine headaches. Migraine headaches affect over 30 million Americans and triptans account for almost $2 billion in sales with the tablet form of triptans representing approximately 80% of prescriptions. Previously, NovaDel reported that use of Sumatriptan OS may lead to a more rapid rise in drug blood levels compared to traditional tablets. NovaDel believes this Pilot Efficacy Study demonstrates that treatment with Sumatriptan OS is safe and effective in relieving migraine headaches at a lower dose than that for sumatriptan tablets.
